ProCE Banner Activity

SUNLIGHT: Phase III Trial of TAS-102 With or Without Bevacizumab for Third-line Treatment of Refractory Metastatic Colorectal Cancer

Conference Coverage
Slideset

Released: January 30, 2023

Expiration: January 29, 2024

Share

Provided by

ProCE Banner

Supporters

This activity was supported by educational grants from

Bristol Myers Squibb

Incyte Corporation

Seagen Inc.